secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001104659-23-058529
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharmaceuticals effects 1-for-20 reverse stock split to regain Nasdaq compliance
--------------------------------------------------------------------------------

- Reverse split ratio 1-for-20 effective 4:01pm ET May 10, 2023; split-adjusted trading begins May 11 under same symbol HEPA.
- Post-split shares outstanding ~3.81M; CUSIP changed to 426897302.
- Primary purpose is to meet Nasdaq minimum bid price requirement for continued listing.
- Proportionate adjustments to equity awards and warrants; fractional shares rounded up to next whole share.
- CEO states split comes ahead of expected Phase 2 ALTITUDE-NASH biomarker results for rencofilstat.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923058529/0001104659-23-058529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000110465923058529/tm2315272d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-058529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer